Skip to main content
. 2020 May 22;11(5):390. doi: 10.1038/s41419-020-2544-7

Fig. 6. Metabolic switch in diabetic kidneys is attenuated by dapagliflozin treatment.

Fig. 6

a Representative images of mice kidney sections from the groups with BODIPY staining. Scale bars, 25 μm. b Quantification of BODIPY positive area in kidney samples from the groups indicated. **p < 0.01 compared with control; ††p < 0.01 compared with diabetes + vehicle. c Triacylglycerol (TG) contents in mouse kidney tissue from the group as indicated. Data are shown as mean ± SD. *p < 0.05 compared with control; **p < 0.01 compared with control; p < 0.05 compared with diabetes + vehicle. df Relative mRNA levels of Pparα (d), Cpt1α (e), and Acadl (f) in samples from the groups indicated. *p < 0.05 compared with control; **p < 0.01 compared with control; p < 0.05 compared with diabetes + vehicle; ††p < 0.01 compared with diabetes + vehicle. gi Relative mRNA levels of Hk2 (g), Ldh (h), and Pdk1 (i) in samples from the groups indicated. *p < 0.05 compared with control; **p < 0.01 compared with control; p < 0.05 compared with diabetes + vehicle; ††p < 0.01 compared with diabetes + vehicle. j Quantification of lactate in kidney tissue samples from the groups indicated. *p < 0.05 compared with control; **p < 0.01 compared with control; ††p < 0.01 compared with diabetes + vehicle. k Western blot analysis of HIF-1α and PHD2 protein and relative protein expression level in the groups as indicated. **p < 0.01 compared with control; p < 0.05 compared with diabetes + vehicle; ††p < 0.01 compared with diabetes + vehicle.